Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SENP2 | Q9HC62 | 17/20 | 0.58 |
| ▸ | SENP1 | Q9P0U3 | 17/20 | 0.58 |
| ▸ | SENP5 | Q96HI0 | 16/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | EDNRA | P25101 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4632927 | 0.90 | SENP2 (0.59) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL4632950 | 0.90 | SENP5 (0.60) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL4634430 | 0.90 | SENP2 (0.59) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL9595149 | 0.88 | SENP2 (0.56) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL4604537 | 0.87 | SENP2 (0.60) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL4634443 | 0.87 | SENP2 (0.62) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL4633951 | 0.87 | KDM4E (0.53) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL4633618 | 0.86 | SENP5 (0.61) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL4634988 | 0.86 | SENP2 (0.54) | KDM4EALDH1A1SENP2SENP1SENP5 | |
| SCHEMBL5034495 | 0.86 | SENP5 (0.59) | KDM4EALDH1A1SENP2SENP1SENP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685121-B1 | ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | claimed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2926660-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-10-07 | — | — | EP | disclosed |
| EP-2926660-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014073623-A1 | METHOD FOR PROMOTING PLANT GROWTH | 住友化学株式会社 (JP) | 2014-05-15 | — | — | WO | disclosed |
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010027875-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-1585745-A4 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | TRILLIUM THERAPEUTICS INC (CA) | 2008-07-09 | — | — | EP | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| EP-1585745-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | Arthron Limited (AU) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004058747-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | ARTHRON LIMITED (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | KDM4E 4057/4885ALDH1A1 4409/4885SENP2 3782/4885 |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | KDM4E 2808/4885ALDH1A1 3832/4885SENP2 4265/4885 |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | FGF2, BROX, BOLA2; BOLA2B | KDM4E 778/4885ALDH1A1 775/4885SENP2 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.